

25th March, 2021

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

We would like to inform you that the Company has subscribed to partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The disclosure pursuant to Regulation 30 of the Listing Regulations and Clause A(1) of Part A, Schedule III of the Listing Regulations, is attached as per “**Annexure I**”.

The above is for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
SVP (LEGAL) & COMPANY SECRETARY

Encl: Annexure I

Annexure I

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 under Clause A(1) of Part A, Schedule III of the aforesaid regulations on subscription of partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) by the Company.

<p>a) Name of the target entity, details in brief such as size, turnover etc.:</p>	<p><i>i) Name of the Target entity:</i> ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), herein after referred to as the Target entity.</p> <p><i>ii) Details of Target entity:</i> The Target entity is a recently incorporated limited liability partnership ('LLP') and has not commenced any business activities.</p>
<p>b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arms-length";</p>	<p>No.</p>
<p>c) Industry to which the entity being acquired belongs;</p>	<p>Healthcare services.</p>
<p>d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity;</p>	<p>Initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices ('GDP') including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India ('Business'). The proposed LLP structure would inter alia ensure transparent and effective competition to the benefit of patients in India.</p>
<p>e) Brief details of any governmental or regulatory approvals required for the acquisition;</p>	<p>None.</p>
<p>f) Indicative time period for completion of the acquisition;</p>	<p>NA</p>
<p>g) Nature of consideration – whether cash consideration or share swap and details of the same;</p>	<p>Cash infusion as capital contribution.</p>
<p>h) Cost of acquisition or the price at which the shares are acquired;</p>	<p>INR 40 crores.</p>



i) Percentage of shareholding / control acquired and/or number of shares acquired;	Upto 20% share of profit/ loss in the Target entity.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>The Target entity has been incorporated on 10th February, 2021.</p> <p>The Target entity is a newly incorporated LLP and has not commenced any business activities. The Target entity would engage in the Business through one or more subsidiary / LLP.</p>

